Telix Pharmaceuticals Limited
TLPPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $593,111 | $594,244 | $188,963 | $281,713 |
| % Growth | -0.2% | 214.5% | -32.9% | – |
| Cost of Goods Sold | $304,769 | $208,447 | $65,082 | $57,738 |
| Gross Profit | $288,343 | $385,797 | $123,881 | $223,975 |
| % Margin | 48.6% | 64.9% | 65.6% | 79.5% |
| R&D Expenses | $123,957 | $75,248 | $45,783 | $98,397 |
| G&A Expenses | $72,510 | $63,660 | $58,682 | $43,866 |
| SG&A Expenses | $146,920 | $111,822 | $64,250 | $105,503 |
| Sales & Mktg Exp. | $74,410 | $48,162 | $0 | $25,938 |
| Other Operating Expenses | $1,679 | $130,349 | $96 | $0 |
| Operating Expenses | $272,556 | $317,419 | $110,129 | $203,900 |
| Operating Income | $15,787 | $68,378 | $13,752 | $20,075 |
| % Margin | 2.7% | 11.5% | 7.3% | 7.1% |
| Other Income/Exp. Net | -$23,134 | -$21,465 | -$4,609 | -$4,688 |
| Pre-Tax Income | -$7,348 | $46,913 | $9,143 | $15,387 |
| Tax Expense | $3,865 | $8,674 | -$2,537 | -$4,144 |
| Net Income | -$3,482 | $38,239 | $11,680 | $19,531 |
| % Margin | -0.6% | 6.4% | 6.2% | 6.9% |
| EPS | -0.01 | 0.12 | 0.035 | 0.06 |
| % Growth | -108.6% | 243.8% | -42.1% | – |
| EPS Diluted | -0.01 | 0.11 | 0.033 | 0.06 |
| Weighted Avg Shares Out | 337,208 | 331,226 | 334,231 | 323,727 |
| Weighted Avg Shares Out Dil | 337,203 | 345,188 | 350,751 | 323,727 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $10,252 | $610 | $566 |
| Interest Expense | $3,920 | $16,521 | $4,943 | $548 |
| Depreciation & Amortization | $10,668 | -$1,995 | $3,660 | $2,092 |
| EBITDA | $8,905 | $76,800 | $40,291 | $22,994 |
| % Margin | 1.5% | 12.9% | 21.3% | 8.2% |